Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
pantoprazole (pantoprazole sodium sesquihydrate)
Takeda GmbH
pantoprazole (pantoprazole sodium sesquihydrate)
40mg
tablets gastro-resistant
Prescription
SUMMARY OF PRODUCT CHARACTERISTICS CONTROLOC ® REGISTRATION NUMBER: TRADE NAME: Controloc ® INTERNATIONAL NON-PROPRIETARY NAME (INN): pantoprazole DOSAGE FORM: gastro-resistant tablets COMPOSITION Each tablet 40 mg contains _CORE _ _Active substance: _ pantoprazole sodium sesquihydrate 45.10 mg equivalent to pantoprazole 40 mg. _Excipients:_ anhydrous sodium carbonate 10.00 mg; mannitol 42.70 mg; crospovidone 50.00 mg; povidone К90 4.00 mg; calcium stearate 3.20 mg; purified water 9.00 mg; _COATING _ Hypromellose-2910 19.00 mg; povidone К25 0.38 mg; titanium dioxide Е 171 0.34 mg; colorant yellow iron oxide Е 172 0.03 mg; propylene glycol 4.25 mg; Eudragit L 30D-55* 14.56 mg; triethyl citrate 1.45 mg. *Eudragit L 30D-55 Suspension composition: Eudragit L 30D-55 (methacrylic acid and ethyl acrylate copolymer [1:1]) 14.13 mg; polysorbate 80 0.33 mg; sodium lauryl sulfate 0.10 mg; OPACODE S-1-16530 BROWN PRINTING INK FOR LABELING TABLETS: shellac 0,036 mg; colorant iron oxide (Е172) red 0,009 mg; colorant iron oxide (Е172) black 0,009 mg; colorant iron oxide (Е172) yellow 0,0009 mg; ammonia solution concentrated 25% 0,001 mg. IDENTIFICATION Oval biconvex, yellow film-coated tablets with a white to off-white core and with brown ink imprinting "P40" on one side. PHARMACOTHERAPEUTIC GROUP: gastric gland secretion suppressing agents – proton pump inhibitors ATC CODE: А02ВС02 PHARMACOLOGICAL PROPERTIES PHARMACODYNAMICS Proton pump inhibitor (Н+ K+ ATPase). Blocks the terminal stage of hydrochloric acid secretion irrespective of the irritant nature. Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells. Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+ K+ ATPase enzyme activity, i.e. blocks the final stage in the production of hydrochloric acid in the stomach. The inhibition of activity is dose-dependent and in result both b Read the complete document